Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...
Eli Lilly (NYSE:LLY) Announces Positive Phase 2 Results For siRNA Therapy Amid 6% Quarterly Price Dip
Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...
The Phase III Study Data Of Stapokibart For Seasonal Allergic Rhinitis Published In Nature Medicine
Results of this phase III trial demonstrated that stapokibart rapidly, significantly, and sustainably controlled both nasal and ocular symptoms in patients with moderate-to-severe SAR, while markedly ...
Arcutis Biotherapeutics (NASDAQ:ARQT) Receives “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) in a research note ...
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $18.80 Consensus PT from Brokerages
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat Ratings ...